2. Immunology/Inflammation
  3. CTLA-4 Interleukin Related
  4. JS007

JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.

For research use only. We do not sell to patients.

JS007

JS007 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

JS007 Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.[1][2]

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human/Mouse/Bovine
IC50 & Target[1]

IL-2

 

In Vitro

JS007 binds to CHO-CTLA-4 cells with an EC50 of 0.22 μg/mL, and its binding affinity is higher than that of the control antibody Ipilimumab (HY-P9901)[1].
JS007 binds to recombinant CTLA-4 with a KD value of 0.21 nM, and its binding affinity is significantly higher than that of the control antibody Ipilimumab[1].
JS007 blocks the interaction between CTLA-4 and B7-1 in CHO-CTLA-4 cells, with an IC50 of 1.096 μg/mL[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JS007 Related Antibodies
In Vivo

JS007 (0.1-1 mg/kg; i.p.; twice weekly) provides superior in vivo tumor suppression efficacy in MC38 syngeneic tumor-bearing human CTLA-4 knock-in C57BL/6 mice compared to Ipilimumab at the same dose, with statistically significant reductions in tumor volume and weight (p < 0.05)[1].
JS007 (0.03-0.1 mg/kg; i.p.; twice weekly) provides substantial in vivo tumor suppression efficacy in H22 syngeneic tumor-bearing human CTLA-4 knock-in BALB/c mice, with statistically significant reductions in tumor volume and weight compared to the isotype control group (p < 0.01)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6-CTLA4tm1(CTLA4)/Bcgen[1]
Dosage: 0.1 mg/kg; 1 mg/kg
Administration: i.p.; twice weekly
Result: Showed significantly lower tumor volume and weight compared to the isotype control group at 1 mg/kg, with values also significantly lower than the ipilimumab 1 mg/kg group (p < 0.05).
Showed significantly lower tumor volume and weight compared to the isotype control group at 0.1 mg/kg, but higher tumor volume and weight than the 1 mg/kg JS007 group.
Animal Model: BALB/c-Ctla4em1(hCTLA4)Smoc[1]
Dosage: 0.03 mg/kg; 0.1 mg/kg
Administration: i.p.; twice weekly
Result: Showed substantially lower tumor volume and weight compared to the isotype control group at 0.1 mg/kg (p < 0.01).
Showed significantly lower tumor volume and weight compared to the isotype control group at 0.03 mg/kg, but higher tumor volume and weight than the 0.1 mg/kg JS007 group.
Showed a better tumor inhibition trend than ipilimumab at 0.1 mg/kg, though the difference was not statistically significant (p > 0.05).
Clinical Trial
Gene ID

1493  [NCBI]

Accession
Target

CTLA4
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

[JS007]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

JS007 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JS007JS 007JS-007CTLA-4Interleukin RelatedCytotoxic T-lymphocyte-associated protein 4CD152ILprimary human CD4+ T cellsIL-2MC38B7-1human CTLA-4 knock-in mouseCHO-CTLA-4 cellsH22T cellB7-2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
JS007
Cat. No.:
HY-P991960
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.